|
Active substance |
Adalimumab |
|
Holder |
AbbVie SA/NV |
|
Status |
Closed |
|
Indication |
Treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies |
|
Public documents |
|
|
Last update |
17/07/2017 |
Humira®
Last updated on